SCHEMBL15035908

SCHEMBL15035908

C=C(c1cc2cnc(Nc3ccc(OC4CCCN(C)C4)cc3)nc2n(Cc2cccn2S(=O)(=O)c2nccs2)c1=O)C(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 1/20 0.35
INSR P06213 1/20 0.34
AXL P30530 1/20 0.34
KDR P35968 1/20 0.34
FGFR4 P22455 7/20 0.34
TNK2 Q07912 3/20 0.34
SRC P12931 1/20 0.34
JAK3 P52333 3/20 0.33
EGFR P00533 1/20 0.32
CCND1 P24385 3/20 0.32
CDK4 P11802 1/20 0.32
CCND2 P30279 1/20 0.32
CCND3 P30281 1/20 0.32
CCNE1 P24864 2/20 0.32
CDK2 P24941 2/20 0.32
CDK6 Q00534 2/20 0.32
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15041647 0.94 CAMK2D (0.36) CAMK2DINSRAXLKDRFGFR4
SCHEMBL15034770 0.80 CAMK2D (0.40) CAMK2DAXLFGFR4TNK2SRC
SCHEMBL15035702 0.78 JAK3 (0.38) CAMK2DINSRAXLKDRTNK2
SCHEMBL15035044 0.77 CDK4 (0.38) CAMK2DINSRAXLKDRFGFR4
SCHEMBL15035774 0.77 PLK2 (0.39) CAMK2DINSRAXLJAK3EGFR
SCHEMBL15035816 0.76 CAMK2D (0.35) CAMK2DINSRAXLKDRTNK2
SCHEMBL15035675 0.75 CCND1 (0.35) FGFR4JAK3CCND1CDK4CCND2
SCHEMBL15034938 0.75 CAMK2D (0.36) CAMK2DINSRAXLKDRFGFR4
SCHEMBL15034834 0.74 CDK4 (0.36) CAMK2DINSRAXLKDRFGFR4
SCHEMBL15035000 0.74 CAMK2D (0.39) CAMK2DJAK3EGFRCCND1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK3, PAK6 CAMK2D 146/4885INSR 3671/4885AXL 935/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 CAMK2D 469/4885INSR 3942/4885AXL 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.